Telomir Pharmaceuticals TELO
NASDAQ TELO
$1.12 -0.05 (-4.27%)
At close: Aug 20, 2026 · 4:00 PM EDT

Telomir Pharmaceuticals (TELO) Total Debt (2023 - 2026)

Telomir Pharmaceuticals (TELO) posted Total Debt of $101000.0 for Q4 2023.

Telomir Pharmaceuticals (TELO) Total Debt (2023 - 2026) Analysis & Trends

Telomir Pharmaceuticals has reported Total Debt for 1 years, with the latest figure at $101000.0 in Q4 2023.

  • Quarterly Total Debt changed N/A year-over-year to $101000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $101000.0 (changed N/A YoY) and the FY2023 annual result came in at $101000.0, changed N/A from the prior year.
  • Total Debt steadied at $101000.0 in Q4 2023 per TELO's latest filing.
  • Over five years, Total Debt peaked at $101000.0 in Q4 2023 and troughed at $101000.0 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn -
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 591.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 1.07 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn -
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 546.77 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - 9.34 Bn
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 770.36 Mn
10 Telomir Pharmaceuticals 68.14 Mn 68.14 Mn - 136,372.00

Historic Data

Download Data
DateValue
Jun 30, 2026 136,372.00
Dec 31, 2023 101,000.00